Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. - Wikidata - awgldk - TriplyDB

Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.

Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.

http://www.wikidata.org/entity/Q37694939

about

A comparison study on the clinical effects of foscarnet sodium injection and interferon on human immunodeficiency virus-infected patients complicated with herpes zoster.Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women.Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women Secreted mucosal antimicrobials in the female reproductive tract that are important to consider for HIV prevention.Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

P2860

Q35765869-2446CDBB-001F-4906-8363-A552135E8FA3 Q36068904-C2473860-8A04-4B09-8AB2-7609EEC27835 Q36306926-891D14BC-C004-4F08-A0A9-C357402AA283 Q36446138-57A653DC-0EF4-4329-8A29-0FA13B8FA639 Q36471518-AAB66E16-ABB1-4D6F-B3E0-D89E30CD9655 Q36644606-219660C4-15D1-4586-83A7-1AB8A3293DFF Q37014243-533A9B2F-2B33-41EC-B4BD-75B33212A40C Q38206217-E62117C7-7BF8-4FBA-98A6-45323C3E1D5F Q55514511-CE5561DB-A333-4429-8E81-3151C35FE4BD

P2860

Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.

http://www.wikidata.org/entity/Q37694939

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiviral activity of genital ...... xposure prophylaxis for HIV-1.

@en

Antiviral activity of genital ...... xposure prophylaxis for HIV-1.

@nl

type

label

Antiviral activity of genital ...... xposure prophylaxis for HIV-1.

@en

Antiviral activity of genital ...... xposure prophylaxis for HIV-1.

@nl

prefLabel

Antiviral activity of genital ...... xposure prophylaxis for HIV-1.

@en

Antiviral activity of genital ...... xposure prophylaxis for HIV-1.

@nl

P1433

Q37694939-97BFB983-05C5-402C-A3CE-460BA799BB4D

P1476

Q37694939-53181F1C-E583-44BE-86F0-DE86403DB1E9

P2093

Q37694939-095C1144-AAC1-475B-A4F2-06A7B38E61C2

Q37694939-15AC8129-C6FB-4CA6-BE96-4971B1958D7D

Q37694939-57EBB9F8-BD0E-472C-8199-605EE49A793B

Q37694939-958D8716-BE17-4D1C-9E0D-8DCFE8DEB7AE

Q37694939-B8F6D4C8-0AB3-4678-A3CF-75ED33282B73

Q37694939-BFFA0001-C42C-4317-BBBA-1F789F080030

Q37694939-C5AB9D0A-4C3D-4099-902A-1BA73A1ADC6B

Q37694939-FE22AF2A-AA84-431F-9BA0-E76210512E32

P2860

Q37694939-056BE242-FCA9-4B0C-A2AB-2595E2FE41B4

Q37694939-1450F761-1856-41F1-8B93-98F451F598A8

Q37694939-24A0A8C7-9130-4A21-BF31-399C2320121C

Q37694939-3544CDB7-65FA-496B-A1A6-3793C3152163

Q37694939-36B2033D-D07F-44B7-8AC6-611673D5FEA6

Q37694939-373D6261-75AA-4FAE-9AD6-2018EEBF4BB5

Q37694939-37E34053-F653-407D-AED9-66555166DE88

Q37694939-3D3FBD8F-A50B-4E6B-A5B9-CB4404A4036D

Q37694939-3DFA1ECA-214A-42B3-A2EA-5C329623AFAF

Q37694939-402F776D-E22C-495C-8FB4-17CD63FD1B9A

P304

Q37694939-C75CF05B-9FBC-41B5-936A-CBA11CC3AF34

P31

Q37694939-285179E7-489E-4A8D-94F3-E65CD39EA92A

P356

Q37694939-E97D247C-141B-43E2-97C5-7432E2CB24C0

P407

Q37694939-411F60DE-72E9-43AD-B332-5D6EBE88BF92

P433

Q37694939-EDF9E6EE-21C0-4546-9682-83F3CCD75CA2

P478

Q37694939-D4CB5D23-F60A-417E-A554-54EC8598457C

P50

Q37694939-236EF27C-CB91-4EAE-B358-CB6DF0E77CC0

Q37694939-464DA0B3-C3E7-49B1-8E8C-E043A93F3804

Q37694939-E5CB8228-41EE-48CF-86AB-B9FB9C0F1674

P577

Q37694939-32245AAE-0E96-4EA4-B402-D9E5F043DEED

P698

Q37694939-9AEEFF2E-A9CF-4E58-9EC0-C7B064BC2C91

P921

Q37694939-B0826365-4BD1-4C45-B93B-C3E55B8207F6

P932

Q37694939-34BD072C-3638-45FE-AF24-728AC8E9D8F4

P356

QAI.0000000000000110

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Antiviral activity of genital ...... exposure prophylaxis for HIV-1

@en

P2093

Ashley Huber

http://www.w3.org/2001/XMLSchema#string

Barbra A Richardson

http://www.w3.org/2001/XMLSchema#string

Betsy C Herold

http://www.w3.org/2001/XMLSchema#string

Colleen Carpenter

http://www.w3.org/2001/XMLSchema#string

Craig W Hendrix

http://www.w3.org/2001/XMLSchema#string

Mark A Marzinke

http://www.w3.org/2001/XMLSchema#string

Nicolette Louissaint

http://www.w3.org/2001/XMLSchema#string

Sharon L Hillier

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

Preexposure prophylaxis for HIV infection among African women

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid.

Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies

P304

65-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000110

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Jeanne M. Marrazzo

Charlene S Dezzutti

Pedro M Mesquita

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24457633

http://www.w3.org/2001/XMLSchema#string

P921

P932

3981887

http://www.w3.org/2001/XMLSchema#string